Your session is about to expire
← Back to Search
D-Cycloserine+iTBS PK Study
Phase 1
Waitlist Available
Led By Alexander McGirr, MD PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up administered at baseline, halfway (week 2), after rtms treatment (week 4), and at one month follow up (week 8)
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a treatment for depression using brain stimulation combined with a medication. It focuses on adults with depression who haven't improved with standard treatments. The study aims to see if adjusting the medication dose based on weight improves outcomes. The medication has been studied for a long time for various anxiety disorders, with mixed results.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ administered at baseline, halfway (week 2), after rtms treatment (week 4), and at one month follow up (week 8)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~administered at baseline, halfway (week 2), after rtms treatment (week 4), and at one month follow up (week 8)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Determine whether blood serum levels of D-cycloserine achieved by weight-based dosing is consistent across time.
Individual differences in D-cycloserine serum concentration will be correlated with clinical outcomes
Individual fidelity to the protocol will be correlated with differential change in
+2 moreSecondary study objectives
Change in Cognitive Function - THINC-integrated tool (THINC-it)- Choice Reaction Time
Change in Cognitive Function - THINC-integrated tool (THINC-it)- Digit Symbol Substitution
Change in Cognitive Function - THINC-integrated tool (THINC-it)- Perceived Deficits Questionnaire - 5 item scale (PDQ-5)
+11 moreOther study objectives
Incidence of Treatment-Emergent Adverse Events
Safety hypothesis: There will be no clinically significant changes in QTc
Safety hypothesis: There will be no clinically significant changes in bloodwork; ALT
+14 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: D-CycloserineExperimental Treatment2 Interventions
Prior to initiating TMS therapy, participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine.
During TMS therapy, participants will orally ingest a capsule containing a weight-based dose of the antibiotic d-cycloserine (dosed 25mg/17.5kg body weight) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulator
2019
Completed Phase 2
~70
D-cycloserine
2013
Completed Phase 4
~1060
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
811 Previous Clinical Trials
892,803 Total Patients Enrolled
31 Trials studying Depression
10,622 Patients Enrolled for Depression
Alexander McGirr, MD PhDPrincipal InvestigatorUniversity of Calgary
4 Previous Clinical Trials
104 Total Patients Enrolled
3 Trials studying Depression
104 Patients Enrolled for Depression